 |
|
|
| |
Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of Phase 3 D-LIVR study.
|
| |
| |
About the Phase 3 D-LIVR Study: oral Lonagarnib/rtv +/- Peg-Lambda 48 weeks - (06/13/22)
Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV - (05/27/22)
Lonafarnib-A new member of the Delta Force? Editorial - (05/27/22)
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study - (05/31/22)
A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (05/31/22)
PREVALENCE OF HEPATITIS DELTA VIRUS (HDV) INFECTION IN THE UNITED STATES: RESULTS FROM AN ICD-10 REVIEW - 25% of HDV in USA is In NYC (Bklyn, Bronx) & NYC Suburb - (06/06/22)
EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
EASL 2022 June 22-26 London
Maria Buti1,2, Ohad Etzion3,4, Adriana Palom1, David Yardeni3,4, Anat Nevo-Shor3,4, Daniela Munteanu3,4, Ingrid Choong5, Lisa Weissfeld6, Mar Riveiro Barciela1,2, Naim Abu-Freha3,4, Ana Barreira1,2, Rob Howard7, Tarik Asselah8, Pietro Lampertico9,10
1Hospital Vall Hebron, Liver Unit, Barcelona, Spain, 2Centro de investigación biomedica en red de enfermedades hepáticas y digestivas, Madrid, Spain, 3Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 4Soroka University Medical Center, Gastroenterology and Liver Diseases, Beer-Sheva, Israel, 5Eiger BioPharmaceuticals, Palo Alto, California, United States, 6Statistics Collaborative Inc, Washington DC, United States, 7Veridical Solutions, Del Mar, California, United States, 8Hôpital Beaujon, Liver Unit, Clichy, France, 9CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Pathophysiology and Transplantation, Milan, Italy, 10Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Gastroenterology and Hepatology, Milan, Italy
|
| |
|
|
|
|
|
